|
AD Connect
  • User
  • Home
  • ADDI Announcements
  • Forums
  • AD Workbench Tech Help
  • Help
  • FAQ
  • Events
  • Video Library
  • Register Now
AD Connect
AD Connect
  • Forums
  • More
  • Cancel
  • New
All Forums

To post a new question, please click into a specific forum.

  • ADDI Researcher Roundtables
  • Research Focus
    • Member Projects
  • Datasets
    • The Airwave Health Monitoring study
    • A blood based 12-miRNA signature of Alzheimer patients - GSE46579
    • A double-blind, randomised, placebo-controlled, parallel-group dose-ranging study
    • An Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease
    • An open-label extension to study AVA100193, to assess the long-term safety and efficacy of rosiglitazone (extended-release tablets) in subjects with mild to moderate Alzheimer's disease
    • An Open-label Extension to Study AVA105640
    • An Open-label Extension to Study AVA102670 and AVA102672
    • An Open Label Single Oral Dose Study
    • A Phase 2a Study
    • A Randomised, Double-blind, Placebo-controlled Study
    • A Randomised, Single-Blind, Placebo-Controlled Study
    • A reference induced pluripotent stem cell line for large-scale collaborative studies
    • A Single Blind, Placebo-controlled, Randomised Study
    • A Study of Semagacestat for Alzheimer's Patients
    • AD Synthetic Patient Data
    • BLSA Open Data
    • BLSA Synthetic Data
    • Brain Imaging Study of Rosiglitazone Efficacy And Safety In Alzheimer's Disease
    • Critical Path for Alzheimer's Disease (CPAD) Database
    • Detection of Alzheimer’s Disease at Mild Cognitive Impairment and Disease Progression Using Autoantibodies as Blood-based Biomarkers - GSE74763
    • DPUK Synthetic Dataset
    • Effects of LY450139
    • The English Longitudinal Study of Ageing
    • Genome-wide DNA methylation profiling in the superior temporal gyrus reveals epigenetic signatures associated with Alzheimer's disease - GSE76105
    • The GERAS Studies
    • Modulation of Beta-amyloid Levels in CSF and Plasma by GSK933776 in Patients with Mild Alzheimer's Disease or Mild Cognitive Impairment
    • Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease
    • Plasma microRNA biomarker detection for mild cognitive impairment using differential correlation analysis - GSE90828
    • PREVENT Dementia Research Programme
    • RNAseq in Alzheimer's Disease patients - GSE53697
    • Rosiglitazone (Extended-Release Tablets) As Adjunctive Therapy for Subjects With Mild To Moderate Alzheimer's Disease
    • Rosiglitazone (Extended-Release Tablets) As Adjunctive Therapy in Subjects With Mild To Moderate Alzheimer's Disease
    • Rosiglitazone (Extended-Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
    • Synthetic EPAD Dataset
    • Whole-blood RNA seq data derived from C9orf72+FTD spectrum cases and controls
  • More
  • Cancel
Share Share on LinkedIn

Welcome the AD Connect Forums page! To view the rest of our forums please log into to AD Connect.

  • Filter

    Terms of Use  |  Privacy Policy  | Feedback